Gemifloxacin Is Effective in Experimental Pneumococcal Meningitis
AUTOR(ES)
Smirnov, A.
FONTE
American Society for Microbiology
RESUMO
In a rabbit model of Streptococcus pneumoniae meningitis, 5 mg of gemifloxacin mesylate (SB-265805) per kg/h reduced the bacterial titers in cerebrospinal fluid (CSF) almost as rapidly as 10 mg of ceftriaxone per kg/h (Δlog CFU/ml/h ± standard deviation [SD], −0.25 ± 0.09 versus −0.38 ± 0.11; serum and CSF concentrations of gemifloxacin were 2.1 ± 1.4 mg/liter and 0.59 ± 0.38 mg/liter, respectively, at 24 h). Coadministration of 1 mg of dexamethasone per kg did not affect gemifloxacin serum and CSF levels (2.7 ± 1.4 mg/liter and 0.75 ± 0.34 mg/liter, respectively, at 24 h) or activity (Δlog CFU/ml/h ± SD, −0.26 ± 0.11).
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=89762Documentos Relacionados
- Gemifloxacin Is Efficacious against Penicillin-Resistant and Quinolone-Resistant Pneumococci in Experimental Meningitis
- Experimental pneumococcal meningitis: role of leukocytes in pathogenesis.
- Rosaramicin Versus Penicillin G in Experimental Pneumococcal Meningitis
- Moxifloxacin in the Therapy of Experimental Pneumococcal Meningitis
- BMS-284756 in Experimental Cephalosporin-Resistant Pneumococcal Meningitis
